TFF PHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.065 USD | +2.74% |
|
-5.28% | -70.58% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 653K | Sales 2025 * | 600K | Capitalization | 6.23M |
|---|---|---|---|---|---|
| Net income 2024 * | -25M | Net income 2025 * | -32M | EV / Sales 2024 * | 9.54 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 10.4 x |
| P/E ratio 2024 * |
-0.31
x | P/E ratio 2025 * |
-0.31
x | Employees | 19 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on TFF Pharmaceuticals, Inc.
More recommendations
More press releases
| 1 day | +8.06% | ||
| 1 week | -3.83% | ||
| Current month | -26.37% | ||
| 1 month | -42.90% | ||
| 3 months | -70.18% | ||
| 6 months | -64.77% | ||
| Current year | -71.37% |
1 week
1.54
2.33
1 month
1.543.47
Current year
1.5411.00
1 year
1.5416.97
3 years
1.54307.00
5 years
1.54528.50
10 years
1.54528.50
| Managers | Title | Age | Since |
|---|---|---|---|
Harlan Weisman
CEO | Chief Executive Officer | 71 | 18-11-30 |
Kirk Coleman
DFI | Director of Finance/CFO | 51 | 18-01-23 |
Zamaneh Mikhak
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-01-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 52 | 18-11-30 | |
Brandi Roberts
BRD | Director/Board Member | 50 | 22-03-24 |
Thomas King
BRD | Director/Board Member | 69 | Dec. 12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 2.065 | +2.74% | 1 765 |
| 24-05-15 | 2.01 | +8.06% | 50,164 |
| 24-05-14 | 1.86 | +2.76% | 32,786 |
| 24-05-13 | 1.81 | -7.18% | 76,533 |
| 24-05-10 | 1.95 | -10.55% | 27,343 |
Delayed Quote Nasdaq, May 15, 2024 at 04:30 pm EDT
More quotes
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.
Calendar
2024-06-04
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.01
USD
Average target price
30
USD
Spread / Average Target
+1,392.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -71.37% | 6.23M | |
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +49.51% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| -22.99% | 18.64B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| +24.01% | 12.1B |
- Stock Market
- Equities
- TFFP Stock